India  

Committed to data transparency on Covaxin, published 9 papers in 12 months: Bharat Biotech

IndiaTimes Saturday, 12 June 2021
0
shares
ShareTweetSavePostSend
 

💡 newsR Knowledge: Other News Mentions

Covaxin Covaxin Vaccine against COVID-19

CDSCO expert panel recommends nod to study on mixing doses of Covaxin, Covishield

An expert panel of India's central drug authority on Thursday recommended granting permission to the Christian Medical College (CMC) in Vellore for conducting a..
IndiaTimes

Brazil's Anvisa provisionally suspends authorisation for exceptional import of 4 million Covaxin doses

After closing the emergency use authorisation (EUA) and Phase-3 clinical trials requests for Bharat Biotech’s Covaxin, Brazil’s health regulator Anvisa..
IndiaTimes

After suspending Covaxin clinical trials, Brazil closes EUA request

After suspending the clinical trials of Covaxin following the termination of Bharat Biotech's MoU with its Brazilian partner Precisa Medicamentos, Brazil’s..
IndiaTimes

COVID-19 vaccine for children likely by September: AIIMS Chief

In view of a probable third wave of the pandemic, vaccination trials on children have been underway in India with Covaxin and Zydus Cadila's ZyCov-D.
DNA

Bharat Biotech Bharat Biotech Indian biotechnology company and vaccine manufacturer

Bharat Biotech commits to supply 500 million doses of Covaxin to Centre for immunisation programme

Bharat Biotech on Friday said it has committed to supply over 500 million doses of its COVID-19 vaccine Covaxin to the Centre under the countrywide immunisation..
IndiaTimes

You Might Like


Related videos from verified sources

Bharat Biotech's Covaxin 77.8 per cent effective in protecting against COVID-19| Oneindia News [Video]

Bharat Biotech's Covaxin 77.8 per cent effective in protecting against COVID-19| Oneindia News

Bharat Biotech's Covaxin is 77.8 per cent effective in protecting against COVID-19 according to data from Phase III trials conducted on 25,800 participants across India. The data was submitted to the..

Credit: Oneindia     Duration: 02:03Published
Bharat biotech submits phase 3 trial data, expert panel meet today| Covaxin | Oneindia News [Video]

Bharat biotech submits phase 3 trial data, expert panel meet today| Covaxin | Oneindia News

Bharat Biotech has submitted Phase 3 clinical trial data for its Covid-19 vaccine, Covaxin, to the Drug Controller General of India (DCGI). The development comes nearly five months after Covaxin was..

Credit: Oneindia     Duration: 02:02Published

Related news from verified sources

Brazil suspends Bharat Biotech's Covaxin order for 20m doses

Brazil will suspend a $324-million contract for Covaxin from Bharat Biotech that has mired President Jair Bolsonaro in accusations of irregularities, the health...
IndiaTimes Also reported by •Zee NewsDNA

Haffkine Bio-Pharma hopeful of Covaxin production in 8 months, targets 22.8 cror

Haffkine Bio-Pharma hopeful of Covaxin production in 8 months, targets 22.8 cror
The Department of Biotechnology has given permission to HBPCL for producing Covaxin under Mission Covid Suraksha. Covaxin has been developed by Bharat Biotech in...
Mid-Day Also reported by •newKerala.comIndiaTimes

Inching towards WHO's emergency use approval for Covaxin: Bharat Biotech


IndiaTimes